StephenMylesPotterMD

Ophthalmology • Aiken, SC

Cornea & External Disease

Physician

Join to view full profile

Dr. Potter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Potter's full profile

Already have an account?

Office
110 Pepper Hill Way
Aiken, SC 29801
Phone+1 803-642-6060

Fax+1 803-642-0754

Education & Training

University of FloridaResidency, Ophthalmology, 2014 - 2017
Medical University of South CarolinaResidency, Internal Medicine, 2013 - 2014
Medical University of South CarolinaClass of 2013

Certifications & Licensure

SC State Medical License 2013 - 2025
GA State Medical License 2019 - 2024
VT State Medical License 2018 - 2020
FL State Medical License 2017 - 2019
American Board of Ophthalmology Ophthalmology

Publications & Presentations

PubMed

5 citations
Use of Autologous Platelets for Lamellar Macular Hole Repair
Andres Gonzalez, Sarina Amin, Omar Iqbal, Stephen Myles Potter, Syed Gibran Khurshid
Case Reports in Ophthalmological Medicine. 2019-05-19
5 citations
Development of Central Serous Chorioretinopathy following Chalazion Removal with Intralesional Triamcinolone Injection: A Case Report.
Luca M. Rosignoli, Stephen Myles Potter, Andres Gonzalez, Sarina Amin, Syed Gibran Khurshid
Case Reports in Ophthalmology. 2018-09-01
2 citations
DEXAMETHASONE INTRAVITREAL IMPLANT FOR X-LINKED (JUVENILE) RETINOSCHISIS.
Sabrina Mukhtar, Stephen Myles Potter, Syed Gibran Khurshid
Retinal Cases & Brief Reports. 2017-01-01

Press Mentions

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal DegenerationSeptember 28th, 2021
AGTC Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 GeneJune 24th, 2021
AGTC Reports Positive 12-Month Data from Highest Dose Groups in Its Ongoing XLRP Phase 1/2 Clinical TrialMay 6th, 2021
Join now to see all